Exelixis’ cabozantinib granted Fast Track designation by FDA for advanced renal cell carcinoma
9 April 2015 | By Victoria White
Exelixis has announced that the FDA has granted Fast Track designation to cabozantinib for treatment of patients with advanced renal cell carcinoma...